Atorvastatin therapy in type 2 diabetes patients: Effects on C-reactive protein levels and cardiovascular risk [Atorvastatintherapie bei Typ-2-Diabetespatienten: Auswirkungen auf den C-reaktiven Protein-Spiegel und das kardiovaskuläre Risiko]

被引：0
|
作者：
Kahl S. [1 ]
机构：
[1] Institut für klinische Diabetologie, Deutsches Diabetes-Zentrum an der Heinrich-Heine-Universität, Leibniz-Zentrum für Diabetesforschung, Auf’m Hennekamp 65, Düsseldorf
来源：
Der Diabetologe | 2015年 / 11卷 / 4期
关键词：
D O I：
10.1007/s11428-015-1400-3
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：327 / 328
页数：1
相关论文
共 27 条
  • [1] Pioglitazon vermindert das kardiovaskuläre Risiko bei Typ-2-DiabetespatientenPioglitazone reduces cardiovascular risk in patients with type 2 diabetes
    R.A. Bierwirth
    M. Dietlein
    C. Franzen
    A. Grünerbel
    C. Hofmann
    J. Merke
    G. Lübben
    E. Karagiannis
    Der Diabetologe, 2008, 4 (7): : 542 - 548
  • [2] Disparate Effects of Atorvastatin Compared With Simvastatin on C-Reactive Protein Concentrations in Patients With Type 2 Diabetes
    Sathyapalan, Thozhukat
    Atkin, Stephen L.
    Kilpatrick, Eric S.
    DIABETES CARE, 2010, 33 (09) : 1948 - 1950
  • [3] Disparate Effects of Atorvastatin Compared to Simvastatin on C-Reactive Protein Concentrations in Patients with Type 2 Diabetes
    Sathyapalan, Thozhukat
    Atkin, Stephen L.
    Kilpatrick, Eric S.
    DIABETES, 2010, 59 : A288 - A289
  • [4] HbA1c und kardiovaskuläres Risiko bei übergewichtigen Patienten mit Typ-2-DiabetesCardiovascular risk and HbA1c levels in overweight patients with type 2 diabetes
    B. Nowotny
    Der Diabetologe, 2012, 8 (7): : 581 - 582
  • [5] The metabolic syndrome in patients with type 1 diabetes mellitus. Associations with cardiovascular risk factors and cardiovascular morbidity [Metabolisches syndrom bei patienten mit diabetes mellitus typ 1: Auswirkungen auf das kardiovaskuläre risikoprofil und die kardiovaskuläre morbidität]
    Reindel J.
    Zander E.
    Heinke P.
    Kohnert K.-D.
    Allwardt C.
    Kerner W.
    Herz, 2004, 29 (5) : 463 - 469
  • [6] Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial
    Soedamah-Muthu, Sabita S.
    Livingstone, Shona J.
    Charlton-Menys, Valentine
    Betteridge, D. John
    Hitman, Graham A.
    Neil, H. Andrew W.
    Bao, Weihang
    DeMicco, David A.
    Preston, Gregory M.
    Fuller, John H.
    Stehouwer, Coen D. A.
    Schalkwijk, Casper G.
    Durrington, Paul N.
    Colhoun, Helen M.
    DIABETOLOGIA, 2015, 58 (07) : 1494 - 1502
  • [7] Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial
    Sabita S. Soedamah-Muthu
    Shona J. Livingstone
    Valentine Charlton-Menys
    D. John Betteridge
    Graham A. Hitman
    H. Andrew W. Neil
    Weihang Bao
    David A. DeMicco
    Gregory M. Preston
    John H. Fuller
    Coen D. A. Stehouwer
    Casper G. Schalkwijk
    Paul N. Durrington
    Helen M. Colhoun
    Diabetologia, 2015, 58 : 1494 - 1502
  • [8] Diagnostic value of serum C-reactive protein as biomarker of cardiovascular risk in patients with type 2 diabetes
    Cam, T. D.
    Hoang, T. A.
    Le, H. T.
    Quyet, H., V
    Trung, P. T.
    Binh, N. T.
    Thuc, V. T. M.
    GENETICS AND MOLECULAR RESEARCH, 2021, 20 (01):
  • [9] Effects of rosiglitazone treatment on levels of C-reactive protein and MMP9 in patients with Type 2 diabetes
    Haffner, SM
    Greenberg, A
    Weston, W
    Fuell, D
    Chen, HZ
    Freed, M
    CIRCULATION, 2001, 104 (17) : 117 - 118
  • [10] Plasma leptin, C-reactive protein and cardiovascular disease risk. factors in patients with type 2 diabetes Mellitus
    Abdella, N
    Mojiminiyi, O
    Moussa, M
    Al Mohammedy, H
    DIABETES, 2003, 52 : A150 - A150
123